Novel non-carbohydrate O-GlcNAcase inhibitors with CNS drug properties as potential treatment for Alzheimer’s disease and tauopathies

Heike Hering; Danielle Graham; Solenne Ousson; Maud Nény; Audrey Gray; Brandy Giacomozzi; John A. Joyce; Vikram Dutt; Michael Busch; Andrew Cameron; Leslie Liu-Bujalski; Henry Yu; Hui Tian; Mark S. Shearman; Anna Quattropani; Bruno Permanne; Christoph Wießner; Dirk Beher

doi:10.1186/1750-1326-8-s1-o17

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Novel non-carbohydrate O-GlcNAcase inhibitors with CNS drug properties as potential treatment for Alzheimer’s disease and tauopathies Heike Hering, Danielle Graham, Solenne Ousson, Maud Neny, Audrey Gray, Brandy Giacomozzi, John Joyce, Vikram Dutt, Michael Busch, Andrew Cameron, Leslie Liu-Bujalski, Henry Yu, Hui Tian, Mark Shearman, Anna Quattropani, Bruno Permanne, Christoph Wiessner, Dirk Beher

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hering et al. (2013) studied this question.

synapsesocial.com/papers/6a724d72e36a167817e3c840 https://doi.org/10.1186/1750-1326-8-s1-o17

View Full Paper

Ask AI

Bookmark

Share

Novel non-carbohydrate O-GlcNAcase inhibitors with CNS drug properties as potential treatment for Alzheimer’s disease and tauopathies

Ask about this paper

Abstract

Discussion

Cite This Study

Novel non-carbohydrate O-GlcNAcase inhibitors with CNS drug properties as potential treatment for Alzheimer’s disease and tauopathies

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading